This is the question people look up at two in the morning and then wish they had not, because the first figure you meet is usually the worst one. So let us start with why that number is out of date, and then with what actually determines your position.
The number that keeps circulating
A frequently quoted meta-analysis from 2001 put the cumulative risk of colorectal cancer in ulcerative colitis at around 2 per cent at 10 years, 8 per cent at 20 years and 18 per cent at 30 years.
Those figures were drawn largely from studies conducted in the 1960s to 1990s, in specialist referral centres, on people with severe disease, before modern maintenance treatment was widespread and before surveillance programmes existed.
More recent population-based data is considerably more reassuring. Several large cohorts now show cumulative risk well under 10 per cent at 30 years even for extensive disease, and some report risk approaching that of the general population. The change is credited to three things: better control of inflammation, widespread use of mesalazine, and surveillance colonoscopy catching precancerous change before it becomes cancer.
The risk is real. It is not the 1970s risk.
What actually drives it
Three factors do most of the work, and the common thread is cumulative inflammation. It is not the diagnosis that raises risk; it is years of inflamed bowel lining.
Extent. The more colon has been inflamed, the higher the risk.
- Proctitis alone — not meaningfully above the general population.
- Left-sided colitis — moderately raised.
- Extensive colitis or pancolitis — the highest of the three.
Duration. Risk begins to climb roughly eight to ten years after symptoms start, which is why surveillance begins around then rather than at diagnosis.
Severity of inflammation over time. This is the one most people do not realise is modifiable. Someone with pancolitis who has been in sustained remission for fifteen years is in a different position from someone with pancolitis and persistent low-grade inflammation over the same period. Histological healing — the lining looking normal under a microscope, not just feeling better — is associated with lower risk.
Then two additional factors:
Primary sclerosing cholangitis. The single biggest multiplier. This inflammatory bile-duct condition occurs in a minority of people with ulcerative colitis and raises colorectal cancer risk substantially. Anyone with both is placed on annual surveillance from the point of diagnosis, regardless of extent or duration. If you have ever had abnormal liver blood tests, it is worth asking whether this has been excluded.
Family history of bowel cancer, particularly in a first-degree relative under 50.
How surveillance works
Colonoscopic surveillance is the mechanism by which this risk is managed, and it is effective — it both reduces cancer deaths and catches cancers at an earlier, more treatable stage.
It starts about ten years after symptoms began — not ten years after diagnosis, which can be a meaningfully different date if you were ill for a while before anyone worked out why.
At that first surveillance colonoscopy you are placed into a risk band, and the band sets the interval. Broadly:
| Risk | Typical interval | Who |
|---|---|---|
| Higher | 1 year | Extensive colitis with severe active inflammation, primary sclerosing cholangitis, previous dysplasia, a stricture, or bowel cancer in a first-degree relative under 50 |
| Intermediate | 3 years | Extensive colitis with mild or moderate inflammation, inflammatory polyps, or bowel cancer in a first-degree relative over 50 |
| Lower | 5 years | Extensive colitis with no active inflammation, or left-sided disease |
Modern surveillance uses chromoendoscopy — a dye sprayed on the bowel lining that makes subtle flat changes visible — with targeted biopsies of anything suspicious. That is more effective than the older approach of taking random biopsies throughout, and it is worth asking whether your unit does it.
Dysplasia: the thing being looked for
Surveillance is not primarily looking for cancer. It is looking for dysplasia — cells that have become abnormal but have not become cancerous. Finding dysplasia is surveillance working as intended.
What happens next depends on what is found:
- A discrete, visible area of dysplasia can often be removed during the colonoscopy, with more frequent surveillance afterwards.
- High-grade or multifocal dysplasia that cannot be removed endoscopically usually prompts a serious discussion about removing the colon, because the likelihood that cancer is already present somewhere is significant.
That second conversation is a difficult one, and it is worth knowing in advance that it exists — it is far easier to absorb as information than as a surprise.
What reduces your risk
Four things, in rough order of how much evidence sits behind them:
- Take maintenance mesalazine consistently. Several studies associate long-term aminosalicylate use with lower colorectal cancer risk, independently of its effect on flares. This is the most common thing people quietly stop doing when they feel well, and it is the one with the longest-delayed consequence.
- Attend every surveillance colonoscopy. The preparation is unpleasant and the appointment is easy to postpone. This is the intervention that demonstrably prevents cancer deaths.
- Aim for proper remission, not just tolerable symptoms. Persistent low-grade inflammation is the thing that accumulates. If you are managing at a constant simmer, that is worth raising rather than accepting.
- The general bowel cancer advice — stop smoking, keep alcohol modest, stay a healthy weight, limit processed and red meat. Not colitis-specific, but all of it applies to you too.
Keeping it in proportion
It is easy to read a page like this and conclude that ulcerative colitis is a countdown. It is not. The large majority of people with ulcerative colitis never develop bowel cancer, the risk is lower than it was a generation ago, and the mechanism for managing it — a camera test every one to five years — is unglamorous but genuinely effective.
What is worth taking from it is narrow and practical: know your extent, know your surveillance interval and when it starts, keep taking the maintenance medication, and do not quietly let an appointment slide. Those four things are most of the difference.
If you do not know your surveillance interval, that is the question for your next appointment.
